Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA DR. REDDYS LAB ALEMBIC PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 19.5 55.1 35.5% View Chart
P/BV x 7.5 5.5 136.4% View Chart
Dividend Yield % 0.5 0.5 105.3%  

Financials

 ALEMBIC PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
DR. REDDYS LAB
Mar-20
ALEMBIC PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6643,363 19.7%   
Low Rs4122,352 17.5%   
Sales per share (Unadj.) Rs208.71,054.2 19.8%  
Earnings per share (Unadj.) Rs31.0121.9 25.4%  
Cash flow per share (Unadj.) Rs37.1190.2 19.5%  
Dividends per share (Unadj.) Rs5.5025.00 22.0%  
Dividend yield (eoy) %1.00.9 116.8%  
Book value per share (Unadj.) Rs144.2938.7 15.4%  
Shares outstanding (eoy) m188.52166.17 113.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.62.7 95.1%   
Avg P/E ratio x17.423.4 74.1%  
P/CF ratio (eoy) x14.515.0 96.5%  
Price / Book Value ratio x3.73.0 122.6%  
Dividend payout %17.720.5 86.5%   
Avg Mkt Cap Rs m101,461474,831 21.4%   
No. of employees `000NA21.7 0.0%   
Total wages/salary Rs m7,46733,802 22.1%   
Avg. sales/employee Rs ThNM8,091.0-  
Avg. wages/employee Rs ThNM1,561.3-  
Avg. net profit/employee Rs ThNM935.8-  
INCOME DATA
Net Sales Rs m39,347175,170 22.5%  
Other income Rs m946,206 1.5%   
Total revenues Rs m39,441181,376 21.7%   
Gross profit Rs m8,73624,421 35.8%  
Depreciation Rs m1,15211,348 10.2%   
Interest Rs m184983 18.7%   
Profit before tax Rs m7,49318,296 41.0%   
Minority Interest Rs m110-   
Prior Period Items Rs m-93561 -16.5%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,568-1,403 -111.7%   
Profit after tax Rs m5,84420,260 28.8%  
Gross profit margin %22.213.9 159.3%  
Effective tax rate %20.9-7.7 -272.8%   
Net profit margin %14.911.6 128.4%  
BALANCE SHEET DATA
Current assets Rs m19,577125,991 15.5%   
Current liabilities Rs m14,89672,141 20.6%   
Net working cap to sales %11.930.7 38.7%  
Current ratio x1.31.7 75.3%  
Inventory Days Days9073 122.8%  
Debtors Days Days45105 43.3%  
Net fixed assets Rs m27,09783,854 32.3%   
Share capital Rs m377831 45.4%   
"Free" reserves Rs m26,811155,157 17.3%   
Net worth Rs m27,188155,988 17.4%   
Long term debt Rs m4,9931,304 382.9%   
Total assets Rs m47,778232,253 20.6%  
Interest coverage x41.719.6 212.6%   
Debt to equity ratio x0.20 2,196.8%  
Sales to assets ratio x0.80.8 109.2%   
Return on assets %12.69.1 137.9%  
Return on equity %21.513.0 165.5%  
Return on capital %23.612.6 187.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45384,193 23.1%   
Fx outflow Rs m6,06539,616 15.3%   
Net fx Rs m13,38844,577 30.0%   
CASH FLOW
From Operations Rs m8,12029,841 27.2%  
From Investments Rs m-7,556-4,923 153.5%  
From Financial Activity Rs m590-25,159 -2.3%  
Net Cashflow Rs m1,153-266 -433.6%  

Share Holding

Indian Promoters % 74.1 25.5 290.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 5.4 53.7%  
FIIs % 9.1 35.3 25.8%  
ADR/GDR % 0.0 18.5 -  
Free float % 13.9 15.3 90.8%  
Shareholders   49,328 75,885 65.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   IPCA LABS  NOVARTIS  ALEMBIC  FRESENIUS KABI ONCO.  WOCKHARDT  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Fell Over 1% Today(Closing)

Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 15, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS